Navigation Links
Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
Date:1/11/2012

HOBOKEN, N.J., Jan. 11, 2012 /PRNewswire/-- Octapharma USA today announced that David E. Holliday has joined the biopharmaceutical company as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, sales and commercial activities and coordination with global portfolio development initiatives.

(Photo:  http://photos.prnewswire.com/prnh/20120111/NY34235 )

Holliday is a senior executive with over 24 years of industry leadership experience, most recently serving as Vice President of Global Marketing Operations & Hemophilia with Baxter Bioscience. Holliday has extensive U.S. and international experience with particular expertise in management, commercial, sales, marketing and business development.

"We are very excited to have David Holliday, a true global leader in our industry, join our senior management team," said Octapharma USA President Flemming Nielsen. "David has critical leadership experience with major multinational pharmaceutical and biotech corporations. He joins Octapharma USA at an extremely important time for our company as our product portfolio in the U.S. will be increasing significantly in the next year and we expect David will be integral to our growth."

Holliday also served as Vice President, Global Marketing Operations and United Kingdom Business Unit Director during his eight years with Baxter Bioscience, which included a number of successful product launches. During his 17-year career with Novartis Pharmaceuticals and Ciba-Geigy Pharmaceuticals, Holliday held progressively responsible management positions, including Business Unit Director of the Transplantation and Matur
'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Octapharma Announces octagam® 5% Again Available for U.S. Purchase
2. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
3. Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
4. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
5. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
6. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
7. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
8. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
11. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia ... reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at ... is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase ...
(Date:7/30/2014)...  Packaging Coordinators, Inc. (PCI) is pleased to announce ... Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered in ... United Kingdom and operates regional offices ... Tokyo , Japan. Penn Pharma offers both ... dosage form manufacturing, as well as Clinical Packaging, Labeling, ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 With the recent ... Ground Zero, the Ground Zero Museum Workshop in the Meatpacking ... bookings. Says the Museum Workshop's Carole Barnes, "We have had ... all the major travel sites who sell us so tourists ... crystal clear as to what we do and what the ...
(Date:7/30/2014)... Decene is an alkene with the formula C10H20. ... with one double bond. 1-Decene enters all reactions ... used as a co-monomer in certain copolymers and ... alcohols, synthetic lubricants, synthetic fatty acids, and alkylated ... customization on this report. , http://www.micromarketmonitor.com/contact/2523613387-request_for_customization.html ...
(Date:7/30/2014)... July 30, 2014 The Europe Phytochemicals ... Phytochemicals & plant extracts market in Europe with analysis ... market in Europe is estimated to grow from around ... at a CAGR of 8.4%, for the given period. ... & plant extracts market report, to get an idea ...
(Date:7/30/2014)... diagnosed with depression as preschoolers are likely to suffer ... research shows. , Depressed preschoolers were 2.5 times more ... middle school than kids who were not depressed at ... School of Medicine in St. Louis. , Their study ... American Journal of Psychiatry . , "It,s the same ...
Breaking Medicine News(10 mins):Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3
... May 29 Conseco, Inc. (NYSE:,CNO) today announced ... made by,Steel Partners II, L.P. to increase its ... of the response letter sent to Steel Partners ... Conseco, Inc.,s insurance companies help protect working American,families ...
... TEL AVIV, Israel, May 29 Elbit Imaging Ltd.,(Nasdaq: ... its results for the,first quarter of 2008., Loss ... 3.5 million,(approximately US$ 1.0 million) of which loss of ... the equity holders of,the Company, while profit of NIS ...
... ROCHELLE, N.Y., May 29 Subjects with type ... glucose levels more frequently and,use the results to ... to a collection of state-of-the-art reports that,comprise a ... 10, Supplement,1) of Diabetes Technology & Therapeutics, a ...
... New research from the Oregon Health & Science ... a wellspring of hope to many patients. , Researchers ... DNA abnormalities that can occur in a gene called ... kinds of acral and mucosal melanomas, which are less ...
... discovered by Tel Aviv University researcher Prof. Illana Gozes ... Alzheimer,s disease. This compound could also treat a number ... as schizophrenia and Parkinson,s, by limiting damage to the ... was found to protect American patients with mild cognitive ...
... bacteria break their metabolic processes into chunks. That may ... have now figured out the factors that tend to ... Santa Fe Institute and Stanford University, together with Anat ... University, constructed the metabolic networks of many species of ...
Cached Medicine News:Health News:Conseco Declines Proposal from Steel Partners II, L.P.; Proposal Would Reduce Conseco's Financial Flexibility and Potentially Disadvantage Other Shareholders 2Health News:Conseco Declines Proposal from Steel Partners II, L.P.; Proposal Would Reduce Conseco's Financial Flexibility and Potentially Disadvantage Other Shareholders 3Health News:Conseco Declines Proposal from Steel Partners II, L.P.; Proposal Would Reduce Conseco's Financial Flexibility and Potentially Disadvantage Other Shareholders 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics 2Health News:Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics 3Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:Appealing the death sentence for brain cells 2
8 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.6 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The Meridian Microruptor V Nd: YAG laser system is indicated for posterior capsulotomy, peripheral iridotomy, and pupillary membranectomy procedures....
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
Medicine Products: